Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
2 Blue Chip Stocks to Buy and Hold Forever
11:30am, Saturday, 07'th Jan 2023
These stocks outperformed tech stocks in 2022 and are reliable investments in tough economic times.
3 No-Brainer Dividend Stocks to Buy in 2023
11:10am, Saturday, 07'th Jan 2023 The Motley Fool
These stocks have what it takes to win over the long run.
3 No-Brainer Dividend Stocks to Buy in 2023
06:10am, Saturday, 07'th Jan 2023
These stocks have what it takes to win over the long run.
CytomX (CTMX) Up 55% on Strategic Partnership With Moderna
06:46pm, Friday, 06'th Jan 2023 Zacks Investment Research
CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.
AbbVie cuts earnings forecast due to milestone payments
06:44pm, Friday, 06'th Jan 2023
AbbVie Inc. executives lowered their outlook for the quarter and year in a filing with the Securities and Exchange Commission late Friday, which cited research and development expenses and milestone p
AbbVie, Goldman Sachs And This Electric Vehicle Manufacturer On CNBC's 'Final Trades'
04:06pm, Friday, 06'th Jan 2023 Benzinga
On CNBC’s "Halftime Report Final Trades," Stephen Weiss of Short Hills Capital Partners said he was shorting Rivian Automotive Inc. (NASDAQ: RIVN) despite the stock recording losses on Thursday.
AbbVie Briefly Breaks Out After Tapping Immunome In $30 Million Cancer Deal
01:45pm, Friday, 06'th Jan 2023
AbbVie stock briefly broke out Friday after the company signed a $30 million deal with small biotech Immunome in antibody development. The post AbbVie Briefly Breaks Out After Tapping Immunome In $30
3 Top U.S. Stocks to Watch in January
01:30pm, Friday, 06'th Jan 2023 The Motley Fool
Considering their potential, all three stocks look like good opportunities today.
Johnson & Johnson Vs. AbbVie: The Better Dividend Aristocrat Buy Might Shock You
12:15pm, Friday, 06'th Jan 2023 Seeking Alpha
Johnson & Johnson and AbbVie Inc. historically fall 70% to 80% less than the S&P 500 Index during bear markets since 1985. Click here to find out which is the better dividend aristocrat.
AbbVie and Immunome Partner to Find New Cancer Treatments
11:17am, Friday, 06'th Jan 2023
Immunome and AbbVie announced a worldwide collaboration and option agreement to discover up to 10 new antibody-target pairs for treating three specific types of tumors using Immunome's technology.
Top Stock Picks for 2023: AbbVie
08:00am, Friday, 06'th Jan 2023
Every day for the next week, we're going to highlight one of Schaeffer's top seven picks for 2023.
Johnson & Johnson Vs. AbbVie: The Better Dividend Aristocrat Buy Might Shock You
07:15am, Friday, 06'th Jan 2023
2023 is likely to start out weak for stocks, and they could potentially fall 15% to 23% in the coming weeks. Healthcare is one of only two sectors that historically goes up in recessions, and dividend
S&P 500's Best Dividend Aristocrats
08:39pm, Thursday, 05'th Jan 2023 The Motley Fool
Investors looking for stability and payout growth should look closer at Dividend Aristocrat stocks.
Final Trades: Abbvie, Goldman Sachs & more
01:58pm, Thursday, 05'th Jan 2023
The "Halftime Report" traders give their top picks to watch for the second half.
8 Upcoming Dividend Increases, Including A Dividend King
01:36pm, Thursday, 05'th Jan 2023
All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 7.4% and a median increase of 6.1%.
